Bibliografia

Bibliografia recomendada

Módulo 1 - PREVENÇÃO PRIMÁRIA E FATORES DE RISCO CARDIOVASCULAR: O QUE HÁ DE NOVO EM 2025

Hipertensão arterial:

  • Guidelines ESC 2024: McEvoy JW. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024 Aug 30:ehae178. doi: 10.1093/eurheartj/ehae178. Epub ahead of print. PMID: 39210715.
  • Ensaio clínico BPROAD: Bi Y et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2412006. Epub ahead of print. PMID: 39555827.
  • Ensaio clínico GMRx2: Rodgers A et al. Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension. J Am Coll Cardiol. 2024 Aug 30:S0735-1097(24)08227-5. doi: 10.1016/j.jacc.2024.08.025. Epub ahead of print. PMID: 39217570.
  • Ensaio clínico: Ojji DB et al. Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial. JAMA. 2024 Aug 31:e2418080. doi: 10.1001/jama.2024.18080. Epub ahead of print. PMID: 39215620; PMCID: PMC11366076.
  • Editorial: Mensah GA. Is a Low-Dose Triple-Drug Combination Pill Protocol the Answer for Hypertension Control in Sub-Saharan Africa? JAMA. 2024 Aug 31. doi: 10.1001/jama.2024.18166. Epub ahead of print. PMID: 39215617.

Dislipidemia:

  • Artigo original: Wu F et al. Non-High-Density Lipoprotein Cholesterol Levels From Childhood to Adulthood and Cardiovascular Disease Events. JAMA. 2024 Jun 4;331(21):1834-1844. doi: 10.1001/jama.2024.4819. PMID: 38607340; PMCID: PMC11151142.
  • Artigo de consenso: Goldstein LB et all. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023 Oct;43(10):e404-e442. doi: 10.1161/ATV.0000000000000164. Epub 2023 Sep 14. Erratum in: Arterioscler Thromb Vasc Biol. 2023 Nov;43(11):e490. doi: 10.1161/ATV.0000000000000165. PMID: 37706297.
  • Artigo de revisão: Ference BA et al. The LDL cumulative exposure hypothesis: evidence and practical applications. Nat Rev Cardiol. 2024 Oct;21(10):701-716. doi: 10.1038/s41569-024-01039-5. Epub 2024 Jul 5. PMID: 38969749.
  • Artigo original: Schubert J et al. Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry. Eur Heart J. 2024 Oct 14;45(39):4204-4215. doi: 10.1093/eurheartj/ehae576. PMID: 39217499; PMCID: PMC11472424.
  • Artigo de revisão: Nielsen RV et al.. Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024 May 28;83(21):2112-2127. doi: 10.1016/j.jacc.2024.02.053. PMID: 38777513.
  • Artigo original: Sniderman AD et al. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur Heart J. 2024 Jul 12;45(27):2410-2418. doi: 10.1093/eurheartj/ehae258. PMID: 38700053; PMCID: PMC11242442.
  • Editorial: Mortensen MB. ApoB triumphs once more over LDL-C and non-HDL-C in risk prediction: ready for guidelines? Eur Heart J. 2024 Jul 12;45(27):2419-2421. doi: 10.1093/eurheartj/ehae257. PMID: 38819813.
  • Artigo de revisão: Nopp S et al. From arteries to veins: the expanding role of lipid-lowering drugs in preventing thrombosis. Eur Heart J. 2024 Sep 14;45(35):3228-3230. doi: 10.1093/eurheartj/ehae492. PMID: 39140442.

Lipoproteina(a):

  • Artigo original: Berman A et al. Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024 Mar, 83 (9) 873–886.
  • Editorial: Wong, N. Lipoprotein(a): Ready for Prime Time?∗ . J Am Coll Cardiol. 2024 Mar, 83 (9) 887–889.
  • Artigo original: Ridker PM et al. Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2405182. Epub ahead of print. PMID: 39216091.
  • Editorial: Blumenthal RS et al. Prevention of Cardiovascular Disease – Don’t Stop Thinking about Tomorrow. N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMe2409080. Epub ahead of print. PMID: 39216097.
  • Artigo original: Nicholls SJ, Ni W, Rhodes GM, et al. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. JAMA 2024;Nov 18:[Epub ahead of print].
  • Artigo original:Nissen SE, Wang Q, Nicholls SJ, et al. Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA 2024;Nov 18:[Epub ahead of print.

Diabetes mellitus:

  • Guidelines ADA 2024: American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009. Erratum in: Diabetes Care. 2024 Jul 1;47(7):1238. doi: 10.2337/dc24-er07a. PMID: 38078590; PMCID: PMC10725810.
  • Guidelines ADA 2025: American Diabetes Association Professional Practice Committee. Introduction and Methodology: Standards of Care in Diabetes-2025. Diabetes Care. 2025 Jan 1;48(1 Suppl 1):S1-S5. doi: 10.2337/dc25-SINT. PMID: 39651982; PMCID: PMC11635031.

Apneia do Sono:

  • Artigo de revisão: Javaheri S et al. Interactions of Obstructive Sleep Apnea With the Pathophysiology of Cardiovascular Disease, Part 1: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024 Sep 24;84(13):1208-1223. doi: 10.1016/j.jacc.2024.02.059. PMID: 39293884.
  • Artigo de revisão: Javaheri S et al. Treatment of OSA and its Impact on Cardiovascular Disease, Part 2: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024 Sep 24;84(13):1224-1240. doi: 10.1016/j.jacc.2024.07.024. PMID: 39293885.

Módulo 2 - Prevenção Secundária em 2025 – Novas estratégias de redução de risco residual após evento cardiovascular

Bloqueadores-beta:

  • Ensaio clínico REDUCE-AMI: Yndigegn T et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024 Apr 18;390(15):1372-1381. doi: 10.1056/NEJMoa2401479. Epub 2024 Apr 7. PMID: 38587241.
  • Ensaio clínico ABYSS: Silvain J et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMoa2404204. Epub ahead of print. PMID: 39213187.
  • Editorial: Jernberg T. Routine Beta-Blockers in Secondary Prevention – Approaching Retirement? N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMe2409646. Epub ahead of print. PMID: 39213193.

Inibidores SGLT2: 

  • Ensaio clínico EMPACT-MI: Butler J et al. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024 Apr 25;390(16):1455-1466. doi: 10.1056/NEJMoa2314051. Epub 2024 Apr 6. PMID: 38587237.
  • Editorial: Rouleau J. Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment. N Engl J Med. 2024 Apr 25;390(16):1524-1526. doi: 10.1056/NEJMe2402719. Epub 2024 Apr 6. PMID: 38587253.
  • Subanálise EMPACT-MI: Hernandez AF et al. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation. 2024 May 21;149(21):1627-1638. doi: 10.1161/CIRCULATIONAHA.124.069217. Epub 2024 Apr 6. PMID: 38581389; PMCID: PMC11115458.
  • Subanálise EMPACT-MI: Udell JA et al. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction. J Am Coll Cardiol. 2024 Jun 11;83(23):2233-2246. doi: 10.1016/j.jacc.2024.03.405. Epub 2024 Apr 6. PMID: 38588929.
  • Editorial: Kochar A et al. Patient Selection Is the Key to EMPACTing Development of Heart Failure After Myocardial Infarction. J Am Coll Cardiol. 2024 Jun 11;83(23):2247-2249. doi: 10.1016/j.jacc.2024.04.027. PMID: 38839198.

Triglicerídeos e risco lipídico residual:

  • Sub-análise REDUCE-IT: Sayah N et al. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. Eur Heart J. 2024 Apr 1;45(13):1173-1176. doi: 10.1093/eurheartj/ehad889. PMID: 38252107; PMCID: PMC10984562.
  • Artigo de revisão: Braunwald E. Triglycerides: the past, the present, and the future. Eur Heart J. 2024 Oct 5;45(37):3780-3781. doi: 10.1093/eurheartj/ehae515. PMID: 39162355.
  • Ensaio clínico RESPECT-EPA: Miyauchi K et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024 Aug 6;150(6):425-434. doi: 10.1161/CIRCULATIONAHA.123.065520. Epub 2024 Jun 14. PMID: 38873793.
  • Editorial: Bittner V. Eicosapentanoic Acid Supplementation for Atherosclerotic Cardiovascular Disease Prevention. Circulation. 2024 Aug 6;150(6):435-438. doi: 10.1161/CIRCULATIONAHA.124.069881. Epub 2024 Aug 5. PMID: 39102483.
  • Artigo de opinião: Tokgözoğlu L et al. Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials. Eur Heart J. 2024 Jul 12;45(27):2377-2379. doi: 10.1093/eurheartj/ehad485. PMID: 37936268.

Inflamação:

  • Ensaio clínico CLEAR (Braço Colquicina): Jolly SS et al. Colchicine in Acute Myocardial Infarction. N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMoa2405922. Epub ahead of print. PMID: 39555823.
  • Ensaio clínico CLEAR (Braço Espironolactona): Jolly SS et al. Routine Spironolactone in Acute Myocardial Infarction. N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMoa2405923. Epub ahead of print. PMID: 39555814.
  • Ensaio clínico COLCOT: Tardif JC et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16. PMID: 31733140.
  • Ensaio clínico LoDoCo2: Nidorf SM et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31. PMID: 32865380.

Obesidade: 

  • Editorial: Kadakia KT et al. The Obesity Revolution Comes to Cardiology. J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08254-8. doi: 10.1016/j.jacc.2024.08.042. Epub ahead of print. PMID: 39218240.
  • Ensaio clínico SELECT: Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24): 2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131.
  • Sub-análise SELECT: Scirica BM et al. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial. J Am Coll Cardiol. 2024 Oct 22;84(17):1632-1642. doi: 10.1016/j.jacc.2024.08.007. Epub 2024 Aug 30. PMID: 39217559.
  • Sub-análise SELECT: Verma S et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by Sex. J Am Coll Cardiol. 2024 Oct 22;84(17):1678-1682. doi: 10.1016/j.jacc.2024.08.022. Epub 2024 Aug 30. PMID: 39217575.
  • Editorial: Pagidipati NJ. Six Substudies From the Semaglutide Trials: Identifying Mechanisms of Benefit and Whom to Treat. J Am Coll Cardiol. 2024 Oct 22;84(17):1663-1665. doi: 10.1016/j.jacc.2024.08.038. Epub 2024 Aug 30. PMID: 39218241.
  • Subanálise FLOW: Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24. PMID: 38785209.
  • Subanálise FLOW: Pratley RE et al. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. J Am Coll Cardiol. 2024 Oct 22;84(17):1615-1628. doi: 10.1016/j.jacc.2024.08.004. Epub 2024 Aug 30. PMID: 39217553.

Reabilitação cardíaca:

  • Artigo de revisão: Thomas RJ. Cardiac Rehabilitation – Challenges, Advances, and the Road Ahead. N Engl J Med. 2024 Feb 29;390(9):830-841. doi: 10.1056/NEJMra2302291. PMID: 38416431.

OUTRAS LEITURAS DO ANO 2024 RECOMENDADAS:

  • Ensaio clínico STOP-ACEi: Bhandari S et al. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med. 2022 Dec 1;387(22):2021-2032. doi: 10.1056/NEJMoa2210639. Epub 2022 Nov 3. PMID: 36326117.
  • Editorial: Volpe M, Patrono C. Discontinuation of renin-angiotensin system inhibitors brings no benefits in severe chronic kidney disease. Eur Heart J. 2024 Jul 9;45(26):2279-2280. doi: 10.1093/eurheartj/ehae248. PMID: 38703142.
  • Ensaio clínico AEGIS-II: Gibson CM et al. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. N Engl J Med. 2024 May 2;390(17):1560-1571. doi: 10.1056/NEJMoa2400969. Epub 2024 Apr 6. PMID: 38587254.
  • Editorial: Ballantyne CM, Nambi V. HDL Therapeutics – Time for a Curtain Call or Time to Reconceptualize? N Engl J Med. 2024 May 2;390(17):1622-1623. doi: 10.1056/NEJMe2403036. Epub 2024 Apr 6. PMID: 38587250.
  • Ensaio clínico VICTORION-INITIATE: Koren MJ et al. An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024 May 21;83(20):1939-1952. doi: 10.1016/j.jacc.2024.03.382. Epub 2024 Apr 7. PMID: 38593947.
  • Editorial: Shapiro MD, German CA. Early Inclisiran Use in Atherosclerotic Cardiovascular Disease: Overcoming Therapeutic Inertia. J Am Coll Cardiol. 2024 May 21;83(20):1953-1956. doi: 10.1016/j.jacc.2024.03.402. PMID: 38749613.
  • Guidelines ESC: Mazzolai L et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024 Aug 30:ehae179. doi: 10.1093/eurheartj/ehae179. Epub ahead of print. PMID: 39210722.

Módulo 3 - Diagnóstico, Abordagem e Tratamento da Doença Coronária em 2024

Guidelines de Síndrome coronária crónica: 

  • Guidelines ESC: Vrints C et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024 Aug 30:ehae177. doi: 10.1093/eurheartj/ehae177. Epub ahead of print. PMID: 39210710.

Terapêutica anti-trombótica:

  • Ensaio clínico ULTIMATE-DAPT: Ge Z et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024 May 11;403(10439):1866-1878. doi: 10.1016/S0140-6736(24)00473-2. Epub 2024 Apr 7. Erratum in: Lancet. 2024 May 11;403(10439):1854. doi: 10.1016/S0140-6736(24)00929-2. PMID: 38599220.
  • Artigo de revisão: Valgimigli M et al. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation. 2024 Jul 23;150(4):317-335. doi: 10.1161/CIRCULATIONAHA.124.069012. Epub 2024 Jul 22. PMID: 39038086.

     

  • Ensaio clínico OPT-BIRISK: Li Y et al. Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial. JAMA Cardiol. 2024 Jun 1;9(6):523-531. doi: 10.1001/jamacardio.2024.0534. PMID: 38630489; PMCID: PMC11024736.
  •  
  • Editorial: Valgimigli M, Landi A. Clopidogrel Monotherapy for Double-Risk Acute Coronary Syndrome. JAMA Cardiol. 2024 Jun 1;9(6):532-533. doi: 10.1001/jamacardio.2024.0547. PMID: 38630487.

     

  • Artigo de revisão: Capranzano P et al. Aspirin-free antiplatelet strategies after percutaneous coronary interventions, European Heart Journal, Volume 45, Issue 8, 21 February 2024, Pages 572–585, https://doi.org/10.1093/eurheartj/ehad876


Síndrome coronária aguda no doente idoso:

  • Ensaio clínico SENIOR-RITA: Kunadian V et al. Invasive Treatment Strategy for Older Patients with Myocardial Infarction. N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407791. Epub ahead of print. PMID: 39225274.


Estratégias de Revascularização Coronária:

  • Meta-análise: Reddy RK et al. Percutaneous Coronary Revascularization Strategies After Myocardial Infarction: A Systematic Review and Network Meta-Analysis. J Am Coll Cardiol. 2024 Jul 16;84(3):276-294. doi: 10.1016/j.jacc.2024.04.051. PMID: 38986670.

     

  • Ensaio clínico FULL REVASC: Böhm F et al. FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction. N Engl J Med. 2024 Apr 25;390(16):1481-1492. doi: 10.1056/NEJMoa2314149. Epub 2024 Apr 8. PMID: 38587995.

     

  • Editorial: Kunadian V. Role of Physiology in the Management of Nonculprit Lesions in Acute Coronary Syndrome. N Engl J Med. 2024 Apr 25;390(16):1527-1529. doi: 10.1056/NEJMe2403527. Epub 2024 Apr 8. PMID: 38588006.

     

  • Ensaio clínico FIRE: Cocco M et al. Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction With or Without ST-Segment Elevation. J Am Coll Cardiol. 2024 Aug 25:S0735-1097(24)07984-1. doi: 10.1016/j.jacc.2024.07.028. Epub ahead of print. PMID: 39217557.

     

  • Ensaio clínico OCCUPI: Hong SJ et al. Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea. Lancet. 2024 Sep 14;404(10457):1029-1039. doi: 10.1016/S0140-6736(24)01454-5. Epub 2024 Sep 2. PMID: 39236729.

     

Suporte circulatório mecânico: 

  • Ensaio clínico DanGer Shock: Møller JE et al. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med. 2024 Apr 18;390(15):1382-1393. doi: 10.1056/NEJMoa2312572. Epub 2024 Apr 7. PMID: 38587239.
  • Ensaio clínico ECLS-SHOCK: Thiele H et al. Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. N Engl J Med. 2023 Oct 5;389(14):1286-1297. doi: 10.1056/NEJMoa2307227. Epub 2023 Aug 26. PMID: 37634145.


OUTRAS LEITURAS DO ANO 2024 RECOMENDADAS:

  • Artigo original: Hamilton DE et al. Merging machine learning and patient preference: a novel tool for risk prediction of percutaneous coronary interventions, European Heart Journal, Volume 45, Issue 8, 21 February 2024, Pages 601–609, https://doi.org/10.1093/eurheartj/ehad836

  • Artigo original – Sinha A et al. Rethinking False Positive Exercise Electrocardiographic Stress Tests by Assessing Coronary Microvascular Function. J Am Coll Cardiol. 2024 Jan, 83 (2) 291–299. https://doi.org/10.1016/j.jacc.2023.10.034

  • Editorial – Beltrame JF et al. Clinical Utility of the Humble Exercise ECG Stress Test. J Am Coll Cardiol. 2024 Jan 16;83(2):300-302. doi: 10.1016/j.jacc.2023.10.036. PMID: 38199707.

     

  • Ensaio clínico TELE-ACS: Alshahrani NS et al. Randomized Trial of Remote Assessment of Patients After an Acute Coronary Syndrome. J Am Coll Cardiol. 2024 Jun 11;83(23):2250-2259. doi: 10.1016/j.jacc.2024.03.398. Epub 2024 Apr 6. PMID: 38588928.

  • Ensaio clínico PULSE-MI: Madsen JM et al. Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction: The PULSE-MI Randomized Clinical Trial. JAMA Cardiol. 2024 Aug 30:e242298. doi: 10.1001/jamacardio.2024.2298. Epub ahead of print. PMID: 39211964; PMCID: PMC11365011.

     

  • Subanálise VALIANT e PARADISE-MI: Curtain JP et al. Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials. JAMA Cardiol. 2024 Aug 7:e242356. doi: 10.1001/jamacardio.2024.2356. Epub ahead of print. PMID: 39110471; PMCID: PMC11307160.

     

  • Ensaio clínico ASSURE DES: Kang DY et al. Aspirin Monotherapy vs No Antiplatelet Therapy in Stable Patients With Coronary Stents Undergoing Low-to-Intermediate Risk Noncardiac Surgery. J Am Coll Cardiol. 2024 Aug 29:S0735-1097(24)08196-8. doi: 10.1016/j.jacc.2024.08.024. Epub ahead of print. PMID: 39217573.

     

  • Editorial: Angiolillo DJ. Management of Antiplatelet Therapy After Coronary Stenting in Patients Requiring Non-Cardiac Surgery. J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08251-2. doi: 10.1016/j.jacc.2024.08.039. Epub ahead of print. PMID: 39222897.

     

  • Ensaio clínico REC-CAGEFREE I: Gao C et al. Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial. Lancet. 2024 Sep 14;404(10457):1040-1050. doi: 10.1016/S0140-6736(24)01594-0. Epub 2024 Sep 2. PMID: 39236727.

     

  • Ensaio clínico SCOFF: Ferreira D et al. Fasting vs no fasting prior to catheterisation laboratory procedures: the SCOFF trial. Eur Heart J. 2024 Sep 1:ehae573. doi: 10.1093/eurheartj/ehae573. Epub ahead of print. PMID: 39217604.

Módulo 4 - A revolução do tratamento da doença valvular em 2025

Estenose aórtica moderada:

  • Artigo de revisão: Bax JJ et al Great debate: symptomatic moderate aortic stenosis should undergo intervention, European Heart Journal, Volume 45, Issue 11, 14 March 2024, Pages 912–921, https://doi.org/10.1093/eurheartj/ehae050

  • Editorial: Fortuni F et al. The Need for Comprehensive Risk Phenotyping in Aortic Stenosis. JACC Cardiovasc Imaging. 2024 Sep;17(9):1041-1043. doi: 10.1016/j.jcmg.2024.05.010. Epub 2024 Jul 10. PMID: 39001734.

  • Artigo original: Dahl JS et al. Cardiac Damage in Early Aortic Stenosis: Is the Valve to Blame? JACC Cardiovasc Imaging. 2024 Sep;17(9):1031-1040. doi: 10.1016/j.jcmg.2024.05.003. Epub 2024 Jun 19. PMID: 38904570.

  • Editorial: Généreux P et al. TAVR in Patients with Moderate Aortic Stenosis and Heart Failure. J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)10056-3. doi: 10.1016/j.jacc.2024.10.088. Epub ahead of print. PMID: 39477044.

  • Ensaio clínico TAVR UNLOAD: Van Mieghem NM et al. Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD. J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)09960-1. doi: 10.1016/j.jacc.2024.10.070. Epub ahead of print. PMID: 39480381.

Intervenção percutânea da válvula aórtica:

  • Ensaio clínico SMART: Herrmann HC et al. Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus. N Engl J Med. 2024 Jun 6;390(21):1959-1971. doi: 10.1056/NEJMoa2312573. Epub 2024 Apr 7. PMID: 38587261.

  • Ensaio clínico POPular PAUSE TAVI: van Ginkel DJ et al. Continuation versus Interruption of Oral Anticoagulation during TAVI. N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2407794. Epub ahead of print. PMID: 39216096.

  • Ensaio clínico NOTION-3: Lønborg J et al. PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation. N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2401513. Epub ahead of print. PMID: 39216095.

     

  • Ensaio clínico EARLY-TAVR: Généreux P et al. Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis. N Engl J Med. 2024 Oct 28. doi: 10.1056/NEJMoa2405880. Epub ahead of print. PMID: 39466903.

     

  • Artigo original: Arnold SV et al. Trends in Transcatheter Aortic Valve Replacement Outcomes: Insights From the STS/ACC TVT Registry. JAMA Cardiol. 2024 Oct 16. doi: 10.1001/jamacardio.2024.3453. Epub ahead of print. PMID: 39412793.
    •  
  • Ensaio clínico DEDICATE-DZHK6: Blankenberg S et al. Transcatheter or Surgical Treatment of Aortic-Valve Stenosis. N Engl J Med. 2024 May 2;390(17):1572-1583. doi: 10.1056/NEJMoa2400685. Epub 2024 Apr 8. PMID: 38588025.

     

  • Editorial: Shah PB. Another Early Win for TAVI in Low-Risk Patients. N Engl J Med. 2024 May 2;390(17):1623-1625. doi: 10.1056/NEJMe2402934. Epub 2024 Apr 8. PMID: 38588008.

     

  • Artigo de revisão: Baumbach A et al. Aortic regurgitation: from mechanisms to management. EuroIntervention. 2024 Sep 2;20(17):e1062-e1075. doi: 10.4244/EIJ-D-23-00840. PMID: 39219357; PMCID: PMC11352546.

     

  • Editorial: Delgado V et al. Severe aortic regurgitation: the limits of TAVI. EuroIntervention. 2024 Sep 2;20(17):e1051-e1052. doi: 10.4244/EIJ-E-24-00045. PMID: 39229834; PMCID: PMC11352525.


Intervenção percutânea na válvula mitral: 

  • Artigo original: Deharo P et al. Mitral transcatheter edge-to-edge repair vs. isolated mitral surgery for severe mitral regurgitation: a French nationwide study, European Heart Journal, Volume 45, Issue 11, 14 March 2024, Pages 940–949, https://doi.org/10.1093/eurheartj/ehae046

  • Artigo original: Naser JA et al. The Natural History of Atrial Functional Mitral Regurgitation. J Am Coll Cardiol. 2024 Apr 23;83(16):1495-1507. doi: 10.1016/j.jacc.2024.02.026. Epub 2024 Mar 25. PMID: 38530687.

     

  • Editorial: Vandervoort PM, Deferm S. The Course of Atrial Functional Mitral Regurgitation: The Atrium Dictates the Path. J Am Coll Cardiol. 2024 Apr 23;83(16):1508-1510. doi: 10.1016/j.jacc.2024.03.357. Epub 2024 Mar 25. PMID: 38631770.

     

  • Ensaio clínico MATTERHORN: Baldus S et al. Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation. N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2408739. Epub ahead of print. PMID: 39216093.

     

  • Ensaio clínico RESHAPE-HF2: Anker SD et al. Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation. N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2314328. Epub ahead of print. PMID: 39216092.

     

  • Subanálise RESHAPE-HF2: Ponikowski P et al. Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2. J Am Coll Cardiol. 2024 Aug 30:S0735-1097(24)08233-0. doi: 10.1016/j.jacc.2024.08.027. Epub ahead of print. PMID: 39217574.
  • Meta-análise: Anker MS et al. Percutaneous Transcatheter Edge-To-Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Meta-Analysis of 3 Randomized Controlled Trials. J Am Coll Cardiol. 2024 Aug 31:S0735-1097(24)08231-7. doi: 10.1016/j.jacc.2024.08.026. Epub ahead of print. PMID: 39217568.
  •  

Intervenção percutânea na válvula tricúspide:

  • Artigo de revisão: Maisano F et al. Transcatheter treatment of the tricuspid valve: current status and perspectives. Eur Heart J. 2024 Mar 14;45(11):876-894. doi: 10.1093/eurheartj/ehae082. PMID: 38426859.

     

  • Artigo original: Dreyfus J et al. TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation, European Heart Journal, Volume 45, Issue 8, 21 February 2024, Pages 586–597, https://doi.org/10.1093/eurheartj/ehad585
    •  
  • Editorial: Patel KP et al. Timing treatment for tricuspid regurgitation, European Heart Journal, Volume 45, Issue 8, 21 February 2024, Pages 598–600, https://doi.org/10.1093/eurheartj/ehad768

  • Ensaio clínico TRISCEND II: Hahn RT et al. Transcatheter Valve Replacement in Severe Tricuspid Regurgitation. N Engl J Med. 2024 Oct 30. doi: 10.1056/NEJMoa2401918. Epub ahead of print. PMID: 39475399.

     

  • Artigo de revisão: Muraru D et al. Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment, European Heart Journal, Volume 45, Issue 11, 14 March 2024, Pages 895–911, https://doi.org/10.1093/eurheartj/ehae088

  • Artigo de revisão: Andreas M et al. Tricuspid valve disease and cardiac implantable electronic devices. Eur Heart J. 2024 Feb 1;45(5):346-365. doi: 10.1093/eurheartj/ehad783. Erratum in: Eur Heart J. 2024 May 13;45(18):1680. doi: 10.1093/eurheartj/ehae221. PMID: 38096587; PMCID: PMC10834167.

     

  • Ensaio clínico TRI.Fr: Multicentric randomised evaluation of the transcatheter edge-to-edge repair in the treatment of severe isolated secondary tricuspid regurgitation – TRI.Fr. Presented by Dr. Erwan Donal at the European Society of Cardiology Congress, London, UK, August 31, 2024.

Módulo 5 - Novidades em 2025 do mundo da Arritmologia e dos Dispositivos Cardíacos

Guidelines ESC 2024 de Fibrilhação Auricular: 

  • ESC Guidelines: Van Gelder IC et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Aug 30:ehae176. doi: 10.1093/eurheartj/ehae176. Epub ahead of print. PMID: 39210723.

Novidades de hipocoagulação oral:

  • Artigo de revisão – Bejjani A et al. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024 Jan, 83 (3) 444–465. https://doi.org/10.1016/j.jacc.2023.10.038

  • Debate: Li S et al. Anticoagulation for Secondary Atrial Fibrillation. N Engl J Med. 2024 Apr 4;390(13):1237-1240. doi: 10.1056/NEJMclde2311699. PMID: 38598582.

  • Subanálise ARTESIA: Lopes RD et al. Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA. J Am Coll Cardiol. 2024 Jul 23;84(4):354-364. doi: 10.1016/j.jacc.2024.05.002. Epub 2024 May 19. PMID: 39019530.

  • Ensaio clínico OCEANIC-AF: Piccini JP et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407105. Epub ahead of print. PMID: 39225267.
  • Artigo de revisão: Gragnano F et al. OCEANIC-AF trial: factor XI inhibitors revolution in atrial fibrillation is on hold. Eur Heart J Cardiovasc Pharmacother. 2024 Sep 10:pvae065. doi: 10.1093/ehjcvp/pvae065. Epub ahead of print. PMID: 39257276.

  • Ensaio clínico EPIC-CAD: Cho MS et al. Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease. N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407362. Epub ahead of print. PMID: 39225258.

  • Editorial: Lip GYH. Atrial Fibrillation and Stable Coronary Artery Disease. N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2409696. Epub ahead of print. PMID: 39225269.

Gestão da fibrilhação auricular detectada por dispositivos:

  • Ensaio clínico GUARD-AF: Lopes RD et al. Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention. J Am Coll Cardiol. 2024 Aug 29:S0735-1097(24)08174-9. doi: 10.1016/j.jacc.2024.08.019. Epub ahead of print. PMID: 39230544.
  • Subanálise GUARD-AF: Singer DE et al. Atrial Fibrillation Burden on a 14-Day ECG Monitor: Findings From the GUARD-AF Trial Screening Arm. JACC Clin Electrophysiol. 2024 Sep 1:S2405-500X(24)00756-4. doi: 10.1016/j.jacep.2024.08.010. Epub ahead of print. PMID: 39297839.
  • Artigo de revisão – Spatz ES et al. Wearable Digital Health Technologies for Monitoring in Cardiovascular Medicine. N Engl J Med. 2024 Jan 25;390(4):346-356. doi: 10.1056/NEJMra2301903. PMID: 38265646.
  • Debate: Sanders P et al. Great debate: device-detected subclinical atrial fibrillation should be treated like clinical atrial fibrillation. Eur Heart J. 2024 Jun 27:ehae365. doi: 10.1093/eurheartj/ehae365. Epub ahead of print. PMID: 38935554.

Ablação da fibrilhação auricular na insuficiência cardíaca: 

  • Meta-análise: Oraii A et al. Atrial Fibrillation Ablation in Heart Failure With Reduced vs Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. JAMA Cardiol. 2024 Jun 1;9(6):545-555. doi: 10.1001/jamacardio.2024.0675. PMID: 38656292; PMCID: PMC11044015.

  • Editorial: Patton KK, Yancy CW. Atrial Fibrillation Ablation in Heart Failure-More Data Are Needed. JAMA Cardiol. 2024 Jun 1;9(6):555. doi: 10.1001/jamacardio.2024.0684. PMID: 38656536.
    •  
  • Ensaio clínico SHAM-PVI: Dulai R et al. Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation: The SHAM-PVI Randomized Clinical Trial. JAMA. 2024 Sep 2:e2417921. doi: 10.1001/jama.2024.17921. Epub ahead of print. PMID: 39221629; PMCID: PMC11369784.

  • Artigo de revisão: Natale A et al. Catheter ablation for atrial fibrillation: indications and future perspective. Eur Heart J. 2024 Sep 26:ehae618. doi: 10.1093/eurheartj/ehae618. Epub ahead of print. PMID: 39322413.

Taquicardia ventricular: 

  • Ensaio clínico VANISH2: Sapp JL et al. Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia. N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2409501. Epub ahead of print. PMID: 39555820.

  • Artigo de revisão: Enriquez A et al. Mapping and Ablation of Premature Ventricular Complexes: State of the Art. JACC Clin Electrophysiol. 2024 Jun;10(6):1206-1222. doi: 10.1016/j.jacep.2024.02.008. Epub 2024 Apr 17. PMID: 38639702.

“Leadless” pacing: 

  • Artigo original: El-Chami MF et al. Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry. Eur Heart J. 2024 Apr 7;45(14):1241-1251. doi: 10.1093/eurheartj/ehae101. PMID: 38426911; PMCID: PMC10998730.

  • Editorial: Vardas PE. Leadless and scarless pacing: towards symbiotic nanogenerators. Eur Heart J. 2024 Apr 7;45(14):1252-1254. doi: 10.1093/eurheartj/ehae124. PMID: 38442144.

  • Ensaio clínico MODULAR ATP: Knops RE et al. A Modular Communicative Leadless Pacing-Defibrillator System. N Engl J Med. 2024 May 18. doi: 10.1056/NEJMoa2401807. Epub ahead of print. PMID: 38767244.
  • Artigo de revisão: Al-Khatib SM. Cardiac Implantable Electronic Devices. N Engl J Med. 2024 Feb 1;390(5):442-454. doi: 10.1056/NEJMra2308353. PMID: 38294976.


OUTRAS LEITURAS DO ANO 2024 RECOMENDADAS:

  • Ensaio clínico RAFT – Sapp JL et al. RAFT Long-Term Study Team. Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure. N Engl J Med. 2024 Jan 18;390(3):212-220. doi: 10.1056/NEJMoa2304542. PMID: 38231622.

  • Artigo original: Lin CS et al. AI-enabled electrocardiography alert intervention and all-cause mortality: a pragmatic randomized clinical trial. Nat Med. 2024 May;30(5):1461-1470. doi: 10.1038/s41591-024-02961-4. Epub 2024 Apr 29. PMID: 38684860.

  • Artigo de consenso: Ntaios G et al. Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC. Eur Heart J. 2024 May 21;45(19):1701-1715. doi: 10.1093/eurheartj/ehae150. PMID: 38685132; PMCID: PMC11107123.

  • Artigo de revisão: Hahn RT et al. Managing Implanted Cardiac Electronic Devices in Patients With Severe Tricuspid Regurgitation: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024 May 21;83(20):2002-2014. doi: 10.1016/j.jacc.2024.02.045. PMID: 38749619.

  • Ensaio clínico TIGHT-K: O’Brien B et al. Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery: The TIGHT K Randomized Clinical Trial. JAMA. 2024 Aug 31:e2417888. doi: 10.1001/jama.2024.17888. Epub ahead of print. PMID: 39215972; PMCID: PMC11366075.
  • Ensaio clínico OPTION: Wazni OM et al. Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2408308. Epub ahead of print. PMID: 39555822.
  • Artigo de revisão: Newman J et al. Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024 Mar, 83 (9) 932–950. https://doi.org/10.1016/j.jacc.2023.12.033

Sessão Especial - Inteligência Artificial na Prática da Cardiologia

  • Artigo de revisão: Elias P et al. Artificial Intelligence for Cardiovascular Care-Part 1: Advances: JACC Review Topic of the Week. J Am Coll Cardiol. 2024 Jun 18;83(24):2472-2486. doi: 10.1016/j.jacc.2024.03.400. Epub 2024 Apr 7. PMID: 38593946.

  • Artigo de revisão: Jain SS et al. Artificial Intelligence in Cardiovascular Care-Part 2: Applications: JACC Review Topic of the Week. J Am Coll Cardiol. 2024 Jun 18;83(24):2487-2496. doi: 10.1016/j.jacc.2024.03.401. Epub 2024 Apr 7. PMID: 38593945.

     

  • Artigo de revisão: Antoniades C, Oikonomou EK. Artificial intelligence in cardiovascular imaging-principles, expectations, and limitations. Eur Heart J. 2021 Sep 24;45(15):1322–6. doi: 10.1093/eurheartj/ehab678. Epub ahead of print. PMID: 34557898; PMCID: PMC11015951.

     

  • Artigo de revisão: Khera R et al. Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024 Jul 2;84(1):97-114. doi: 10.1016/j.jacc.2024.05.003. PMID: 38925729.
  • Editorial: Hull SC et al. Echoes of Concern-AI and Moral Agency in Medicine. JAMA Cardiol. 2024 Sep 2. doi: 10.1001/jamacardio.2024.3512. Epub ahead of print. PMID: 39221501.
    •  
  • Artigo de revisão: Oikonomou EK et al. Artificial intelligence-enhanced patient evaluation: bridging art and science. Eur Heart J. 2024 Sep 14;45(35):3204-3218. doi: 10.1093/eurheartj/ehae415. PMID: 38976371; PMCID: PMC11400875.

Módulo 7 - Abordagem, diagnóstico e tratamento da Insuficiência Cardíaca em 2025

Insuficiência cardíaca com fração de ejeção reduzida: 

  • Artigo de consenso: Maddox T. et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. null2024, 0 (0). https://doi.org/10.1016/j.jacc.2023.12.024

  • Artigo de consenso: Hollenberg SM et al. 2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024 Aug 2:S0735-1097(24)07449-7. doi: 10.1016/j.jacc.2024.06.002. Epub ahead of print. PMID: 39127954.

     

  • Artigo de revisão: Bozkurt B. Contemporary pharmacological treatment and management of heart failure. Nat Rev Cardiol. 2024 Aug;21(8):545-555. doi: 10.1038/s41569-024-00997-0. Epub 2024 Mar 26. PMID: 38532020.

Restrição hídrica e de sal na insuficiência cardíaca:

  • Artigo de consenso: Mullens W et al. Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. Eur J Heart Fail. 2024 Apr;26(4):730-741. doi: 10.1002/ejhf.3244. Epub 2024 Apr 12. PMID: 38606657.

Revascularização na cardiopatia isquémica

  • Ensaio clínico REVIVED-BCIS2: Perera D et al. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022 Oct 13;387(15):1351-1360. doi: 10.1056/NEJMoa2206606. Epub 2022 Aug 27. PMID: 36027563.

     

  • Subanálise REVIVED-BCIS2: Ezad SM et al. Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy. J Am Coll Cardiol. 2024 Jul 23;84(4):340-350. doi: 10.1016/j.jacc.2024.04.043. Epub 2024 May 15. PMID: 38759904; PMCID: PMC11250908.
  • Editorial: Ahmed-Jushuf F et al. Does REVIVED Complete You? J Am Coll Cardiol. 2024 Jul 23;84(4):351-353. doi: 10.1016/j.jacc.2024.05.024. PMID: 39019529.

Diagnóstico da insuficiência cardíaca com fração de ejeção preservada: 

  • Artigo de revisão: Redfield MM et al. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023 Mar 14;329(10):827-838. doi: 10.1001/jama.2023.2020. PMID: 36917048.
  • Artigo de consenso: Kittleson MM et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 May 9;81(18):1835-1878. doi: 10.1016/j.jacc.2023.03.393. Epub 2023 Apr 19. PMID: 37137593.

     

  • Artigo de revisão: Harada T et al. Imaging and mechanisms of heart failure with preserved ejection fraction: a state-of-the-art review. Eur Heart J Cardiovasc Imaging. 2024 Oct 30;25(11):1475-1490. doi: 10.1093/ehjci/jeae152. PMID: 38912836.

     

  • Artigo de revisão: Dimond M et al. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping. J Am Coll Cardiol HF. 2024 Mar, 12 (3) 451–460. https://doi.org/10.1016/j.jchf.2023.11.005

  • Artigo de revisão: Istratoaie S et al. How to diagnose heart failure with preserved ejection fraction. Eur Heart J Cardiovasc Imaging. 2024 Oct 30;25(11):1505-1516. doi: 10.1093/ehjci/jeae183. PMID: 39012791.

     

  • Editorial: Packer M. A reclassification of heart failure based on recognition of heart failure with normal to supernormal ejection fraction, a clinically common form of cardiac contracture, with distinctive pathophysiological and therapeutic features. Eur J Heart Fail. 2023 May;25(5):669-672. doi: 10.1002/ejhf.2849. Epub 2023 Apr 18. PMID: 37013269.
  • Artigo original: Kondo T et al. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification? Circulation. 2023 Aug 29;148(9):732-749. doi: 10.1161/CIRCULATIONAHA.122.063642. Epub 2023 Jun 27. PMID: 37366061.

Finerenona:

  • Ensaio clínico FINEARTS-HF: Solomon SD et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407107. Epub ahead of print. PMID: 39225278.

     

  • Subanálise FINEARTS-HF: Vardeny O et al. Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. 2024 Nov 17:e244539. doi: 10.1001/jamacardio.2024.4539. Epub ahead of print. PMID: 39550716; PMCID: PMC11571067.
  • Editorial: Fonarow GC et al. The Fine Art and Science of Translating Trials Results Into Clinical Practice. JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4550. Epub ahead of print. PMID: 39550722.

Obesidade na insuficiência cardíaca com fração de ejeção preservada:

  • Artigo de revisão: Dronkers J et al. Heart Failure and Obesity: Unraveling Molecular Mechanisms of Excess Adipose Tissue. J Am Coll Cardiol. 2024 Oct 22;84(17):1666-1677. doi: 10.1016/j.jacc.2024.07.016. PMID: 39415402.

     

  • Ensaio clínico STEP-HFpEF: Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25. PMID: 37622681.

     

  • Subanálise STEP-HFpEF: Verma S et al. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials. J Am Coll Cardiol. 2024 Jun 19:S0735-1097(24)07445-X. doi: 10.1016/j.jacc.2024.06.001. Epub ahead of print. PMID: 38913003.

     

  • Editorial: Ostrominski JW, Lala A. Incretin-Based Therapies in Women With Obesity-Related HFpEF: Time to STEP Into a Paradigm of Integrated Care. J Am Coll Cardiol. 2024 Jun 23:S0735-1097(24)07557-0. doi: 10.1016/j.jacc.2024.06.006. Epub ahead of print. PMID: 38917937.

     

  • Subanálise STEP-HFpEF: Schou M et al. Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program. J Am Coll Cardiol. 2024 Jul 16;84(3):247-257. doi: 10.1016/j.jacc.2024.04.038. Epub 2024 Jun 23. PMID: 38913004.

     

  • Editorial: Cannata A, Bromage DI, Piper SE, McDonagh TA. Heart Failure With Preserved Ejection Fraction: Prioritizing Patients’ Symptoms. J Am Coll Cardiol. 2024 Jul 16;84(3):258-259. doi: 10.1016/j.jacc.2024.05.017. Epub 2024 Jun 23. PMID: 38913002.

     

  • Subanálise STEP-HFpEF: Solomon SD et al. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure. J Am Coll Cardiol. 2024 Aug 29:S0735-1097(24)08192-0. doi: 10.1016/j.jacc.2024.08.021. Epub ahead of print. PMID: 39217567.

     

  • Ensaio clínico SUMMIT: Packer M et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2410027. Epub ahead of print. PMID: 39555826.

     

  • Editorial: Kittipibul V et al. Effects of GLP-1 Receptor Agonists on Heart Failure Outcomes: The FLOW of Evidence. J Am Coll Cardiol. 2024 Oct 22;84(17):1629-1631. doi: 10.1016/j.jacc.2024.08.016. Epub 2024 Aug 30. PMID: 39217554.

     

  • Subanálise FLOW: Pratley RE et al. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. J Am Coll Cardiol. 2024 Aug 23:S0735-1097(24)08116-6. doi: 10.1016/j.jacc.2024.08.004. Epub ahead of print. PMID: 39217553.

     

  • Sub-análise STEP-HFpEF: Verma S et al. Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program. J Am Coll Cardiol. 2024 Oct 22;84(17):1646-1662. doi: 10.1016/j.jacc.2024.08.028. Epub 2024 Aug 30. PMID: 39217564.

     

  • Sub-análise STEP-HFpEF: Verma S et al. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program. J Am Coll Cardiol. 2024 Oct 22;84(17):1603-1614. doi: 10.1016/j.jacc.2024.08.023. Epub 2024 Aug 30. PMID: 39217565; PMCID: PMC11486552.

     

  • Ensaio clínico STEP-HFpEF DM: Kosiborod MN et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024 Apr 18;390(15):1394-1407. doi: 10.1056/NEJMoa2313917. Epub 2024 Apr 6. PMID: 38587233.

OUTRAS LEITURAS DO ANO 2024 RECOMENDADAS:

  • Meta-análise: Zafeiropoulos S et al. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis. JACC Heart Fail. 2024 Apr;12(4):616-627. doi: 10.1016/j.jchf.2023.07.014. Epub 2023 Aug 30. PMID: 37656079.

     

  • Artigo de revisão: Mullens W et al. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2024 Jan 25. doi: 10.1002/ejhf.3150.

     

  • Artigo de revisão: Herrmann J et al. The year in cardiovascular medicine 2023: the top 10 papers in cardio-oncology. Eur Heart J. 2024 Jul 9;45(25):2197-2200. doi: 10.1093/eurheartj/ehae194. PMID: 38591649.

     

  • Ensaio clínico ARISE-HF: Januzzi JL Jr et al. Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy. J Am Coll Cardiol. 2024 Jul 9;84(2):137-148. doi: 10.1016/j.jacc.2024.03.380. Epub 2024 Apr 8. PMID: 38597864.

     

  • Artigo de consenso: Kittleson MM et al. 2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures. Circ Cardiovasc Qual Outcomes. 2024 Aug 8:e000132. doi: 10.1161/HCQ.0000000000000132. Epub ahead of print. PMID: 39116212.

     

  • Subanálise PARADIGM-HF e PARAGON-HF: Lu H et al. Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials. JAMA Cardiol. 2024 Aug 30:e242566. doi: 10.1001/jamacardio.2024.2566. Epub ahead of print. PMID: 39210725; PMCID: PMC11365012.

     

  • Subanálise DELIVER: Vardeny O et al. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial. JAMA Cardiol. 2024 Mar 1;9(3):283-289. doi: 10.1001/jamacardio.2023.5318. PMID: 38265835; PMCID: PMC10809142.

     

  • Subanálise STRONG-HF: Cotter G et al. Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial. JAMA Cardiol. 2024 Feb 1;9(2):114-124. doi: 10.1001/jamacardio.2023.4553. PMID: 38150260; PMCID: PMC10753435.

Módulo 8 - O “Novo Mundo” das Miocardiopatias e da Insuficiência Cardíaca em 2025

Tratamento da cardiomiopatia amiloide por transtirretina: 

  • Artigo original: Porcari A et al. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2024 Jun 18;83(24):2411-2422. doi: 10.1016/j.jacc.2024.03.429. PMID: 38866445.

     

  • Editorial: Pinney SP et al. As Good as it Gets: SGLT2 Inhibitors in Cardiac Amyloidosis. J Am Coll Cardiol. 2024 Jun 18;83(24):2423-2425. doi: 10.1016/j.jacc.2024.04.024. PMID: 38866446.

     

  • Ensaio clínico HELIOS-B: Fontana M et al. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMoa2409134. Epub ahead of print. PMID: 39213194.

     

  • Ensaio clínico Nexiguran Ziclumeran (Fase 1): Fontana M et al. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2412309. Epub ahead of print. PMID: 39555828.

     

  • Artigo de revisão:  Argiro A et al. Applications of Gene Therapy in Cardiomyopathies. J Am Coll Cardiol HF. 2024 Feb, 12 (2) 248–260. https://doi.org/10.1016/j.jchf.2023.09.015
  • Artigo de revisão: Alwan L et al. Current and Evolving Multimodality Cardiac Imaging in Managing Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol Img. 2024 Feb, 17 (2) 195–211. https://doi.org/10.1016/j.jcmg.2023.10.010

Guidelines de Miocardiopatia Hipertrófica:

  • Guidelines AHA 2024: Ommen SR et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jun 4;149(23):e1239-e1311. doi: 10.1161/CIR.0000000000001250. Epub 2024 May 8. PMID: 38718139.
  • Mensagens chave guidelines AHA: Coylewright M et al. 2024 Hypertrophic Cardiomyopathy Guideline-at-a-Glance. J Am Coll Cardiol. 2024 Jun 11;83(23):2406-2410. doi: 10.1016/j.jacc.2024.04.002. Epub 2024 May 8. PMID: 38727648.

Tratamento da Miocardiopatia Hipertrófica Obstrutiva

  • Artigo de revisão: Abbasi M et al. Obstruction in Hypertrophic Cardiomyopathy: Many Faces. J Am Soc Echocardiogr. 2024 Jun;37(6):613-625. doi: 10.1016/j.echo.2024.02.010. Epub 2024 Feb 28. PMID: 38428652
    •  
  • Artigo original: Greenbaum AB et al. Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction. J Am Coll Cardiol. 2024 Apr 9;83(14):1257-1272. doi: 10.1016/j.jacc.2024.02.007. Epub 2024 Mar 11. PMID: 38471643; PMCID: PMC10990778.

     

  • Ensaio clínico SEQUOIA-HCM: Maron MS et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2024 May 30;390(20):1849-1861. doi: 10.1056/NEJMoa2401424. Epub 2024 May 13. PMID: 38739079.

     

  • Editorial: Ommen SR. Sixty Years of Hemodynamic Pharmacology in Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2024 May 30;390(20):1914-1915. doi: 10.1056/NEJMe2403937. Epub 2024 May 13. PMID: 38739083.

Cuidados paliativos em Cardiologia

  • Artigo de revisão: Gelfman LP et al. Palliative Care Across the Spectrum of Heart Failure. JACC Heart Fail. 2024 Jun;12(6):973-989. doi: 10.1016/j.jchf.2024.01.010. Epub 2024 Mar 6. PMID: 38456852.

     

  • Artigo de revisão: Blum M et al. Palliative care in heart failure guidelines: A comparison of the 2021 ESC and the 2022 AHA/ACC/HFSA guidelines on heart failure. Eur J Heart Fail. 2023 Oct;25(10):1849-1855. doi: 10.1002/ejhf.2981. Epub 2023 Aug 10. PMID: 37492904.

     

  •  Artigo de revisão: Godfrey S et al. Expanding the Paradigm for Cardiovascular Palliative Care. Circulation. 2023 Sep 26;148(13):1039-1052. doi: 10.1161/CIRCULATIONAHA.123.063193. Epub 2023 Sep 25. PMID: 37747951; PMCID: PMC10539017.

OUTRAS LEITURAS DO ANO 2024 RECOMENDADAS:

  • Artigo de consenso: Cheng RK et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation. 2024 May 21;149(21):e1197-e1216. doi: 10.1161/CIR.0000000000001240. Epub 2024 Apr 18. PMID: 38634276.
  • Ensaio clínico IMPROVE-HCM: Maron MS et al. Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024 May 28;83(21):2037-2048. doi: 10.1016/j.jacc.2024.03.387. Epub 2024 Apr 8. PMID: 38599256.

     

  • Artigo de revisão: Del Franco A et al. Atlas of Regional Left Ventricular Scar in Nonischemic Cardiomyopathies: Substrates and Etiologies. JACC Adv. 2024 Aug 19;3(10):101214. doi: 10.1016/j.jacadv.2024.101214. PMID: 39246577; PMCID: PMC11380395.
    •  
  • Artigo de revisão: Domínguez F et al. Alcoholic cardiomyopathy: an update. Eur Heart J. 2024 Jul 9;45(26):2294-2305. doi: 10.1093/eurheartj/ehae362. PMID: 38848133; PMCID: PMC11231944.

     

  • Ensaio clínico EXPLORER-HCM: Olivotto I et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29. Erratum in: Lancet. 2020 Sep 12;396(10253):758. doi: 10.1016/S0140-6736(20)31872-9. PMID: 32871100.
  • Ensaio clínico MAVA-LTE: Rader F et al. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort. JACC Heart Fail. 2024 Jan;12(1):164-177. doi: 10.1016/j.jchf.2023.09.028. PMID: 38176782.
  •